Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy

Oncology Reports

Volumn 31, Issue 2, 2014, Pages 613-618

  Omura, Tetsuya ^a   Shimada, Yutaka ^a   Nagata, Takuya ^a   Okumura, Tomoyuki ^a   Fukuoka, Junya ^a   Yamagishi, Fuminori ^b   Tajika, Sadakatsu ^c   Nakajima, Sanae ^d   Kawabe, Atsushi ^d   Tsukada, Kazuhiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Itoigawa General Hospital   (Japan)

^c Saiseikai Toyama Hospital   (Japan)

^d ASAHI UNIVERSITY   (Japan)

Author keywords

Gastric cancer; microRNA; Relapse; S 1

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; MICRORNA; MICRORNA 422A; MICRORNA 4732 5P; MICRORNA 4758 3P; MICRORNA 92B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; GASTRECTOMY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RNA ANALYSIS; STOMACH CANCER;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; STOMACH NEOPLASMS; SURVIVAL; TEGAFUR;

EID: 84892411280     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2900     Document Type: Article

References (24)

1. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H and Sasako M: Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 18: 5992-6000, 2012.
2. Fujimoto S, Akao T, Itoh B, Koshizuka I, Koyano K, Kitsukawa Y, Takahashi M, Minami T, Ishigami H, Miyazaki M, Amamiya K, Ohyama Y, Ono K, Kure M, Itoh Kenjiro and Hikosaka Protracted oral chemotherapy with fluorinated pyrimidines as an adjuvant to surgical treatment for stomach cancer. Ann Surg 185: 462-466, 1977.
3. Earle CC and Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting meta-analysis of randomized trials. Eur J Cancer 35: 1059-1064, 1999.
4. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R and Torri V: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. Ann Oncol 11: 837-843, 2000.
5. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A and Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007.
6. Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 14: 113-123, 2011.
7. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage or III gastric cancer. J Clin Oncol 29: 4387-4393, 2011.
8. Calin G and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
10. Hummel R, Hussey DJ and Haier J: MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 46: 298-311, 2010.
11. Koizumi W, Narahara H, Hara T, Takagane A, Akiya Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H and Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
12. Osawa S, Shimada Y, Sekine S, Okumura T, Nagata T, Fukuoka J and Tsukada K: MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-embedded samples. Oncol Lett 613-619, 2011.
13. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R and Cormier JN: Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 103: 129-142, 2011.
14. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M and Ju J: Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 3: 317-324, 2006.
15. Haug BH, Henriksen JR, Buechner J, Geerts D, Tømte E, Kogner P, Martinsson T, Flægstad T, Sveinbjørnsson B and Einvik C: MYCN-regulated miRNA-92 inhibits secretion the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis 32: 1005-1012, 2011.
16. Wang K, Wang X, Zou J, Zhang A, Wan Y, Pu P, Song Z, Qian C, Chen Y, Yang S and Wang Y: miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase. Neuro Oncol 15: 578-588, 2013.
17. Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, Sasaki Y and Hirayama R: Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer 119: 1927-1933, 2006.
18. Jeung HC, Rha SY, Shin SJ, Lim SJ, Roh JK, Noh SH and Chung HC: Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. Anticancer Drugs 22: 801-810, 2011.
19. Kai K, Kitajima Y, Hiraki M, Satoh S, Tanaka M, Nakafusa Y, Tokunaga O and Miyazaki K: Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens. Cancer Lett 258: 45-54, 2007.
20. Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY and Alberti L: Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer 129: 680-690, 2011.
21. Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K, Kiss I, Vyzula R and Slaby O: Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 16: 2655-2666, 2012.
22. Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, Hur K, Yoo MW, Lee HJ, Yang HK and Kim VN: Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res 37: 1672-1681, 2009.
23. Zhang CZ, Han L, Zhang AL, Fu YC, Yue X, Wang GX, Jia ZF, Pu PY, Zhang QY and Kang CS: MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 10: 367-376, 2010.
24. Zhang X, Yan Z, Zhang J, Gong L, Li W, Cui J and Liu Y: Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol 22: 2257-2266, 2011.